BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21039327)

  • 21. Management of borderline tumors of the ovary: state of the art.
    Tropé C; Kaern J
    Semin Oncol; 1998 Jun; 25(3):372-80. PubMed ID: 9633850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Feasibility and limits of laparoscopic treatment of borderline ovarian tumours].
    Fauvet R; Poncelet C; Daraï E
    Gynecol Obstet Fertil; 2006 Jun; 34(6):470-8. PubMed ID: 16677839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term studies of patients with borderline tumors of the ovaries].
    Adam R; Reinhardt M; Thyselius D; Tulusan AH
    Geburtshilfe Frauenheilkd; 1989 Dec; 49(12):1039-43. PubMed ID: 2558944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.
    Ren J; Peng Z; Yang K
    Gynecol Oncol; 2008 Aug; 110(2):162-7. PubMed ID: 18495223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serous borderline ovarian tumors].
    Zipprich K; Albrecht G; Canzler E
    Zentralbl Gynakol; 1985; 107(3):159-68. PubMed ID: 3984570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline tumors of the ovary and peritoneal implants.
    Denkert C; Dietel M
    Verh Dtsch Ges Pathol; 2005; 89():84-91. PubMed ID: 18035677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Borderline tumours of the ovary and fertility.
    Morice P
    Eur J Cancer; 2006 Jan; 42(2):149-58. PubMed ID: 16326097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclooxygenase-2 expression in borderline ovarian tumors.
    Ferrandina G; Zannoni GF; Ranelletti FO; Legge F; Gessi M; Salutari V; Gallotta V; Lauriola L; Scambia G
    Gynecol Oncol; 2004 Oct; 95(1):46-51. PubMed ID: 15385109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Borderline ovarian tumors and extended patient follow-up: an individual institution's experience.
    Rettenmaier MA; Lopez K; Abaid LN; Brown JV; Micha JP; Goldstein BH
    J Surg Oncol; 2010 Jan; 101(1):18-21. PubMed ID: 19798685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.
    Elit LM; Levine MN; Gafni A; Whelan TJ; Doig G; Streiner DL; Rosen B
    Gynecol Oncol; 1996 Sep; 62(3):329-35. PubMed ID: 8812525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Laparoscopic treatment of borderline ovarian tumor: analysis of 54 patients and clinical outcomes].
    Camatte S; Deffieux X; Castaigne D; Thoury A; Fourchotte V; Pautier P; Lhommé C; Duvillard P; Morice P
    Gynecol Obstet Fertil; 2005 Jun; 33(6):395-402. PubMed ID: 15927503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fertility and recurrence results of conservative surgery for borderline ovarian tumors.
    Boran N; Cil AP; Tulunay G; Ozturkoglu E; Koc S; Bulbul D; Kose MF
    Gynecol Oncol; 2005 Jun; 97(3):845-51. PubMed ID: 15896834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
    Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
    Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canadian women's perspectives on ovarian cancer.
    Fitch MI; Gray RE; DePetrillo D; Franssen E; Howell D
    Cancer Prev Control; 1999 Feb; 3(1):52-60. PubMed ID: 10474753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The diagnostic and prognostic values of assay of serum vascular endothelial growth factor in epithelial ovarian cancer].
    Tan X; Shen K; Liu D; Xu X; Lang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Aug; 22(4):352-5. PubMed ID: 12903449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.